Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

November 2, 2009

Primary Completion Date

November 10, 2010

Study Completion Date

November 10, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

GSK239512

Histamine H3 Antagonist

DRUG

Placebo

Placebo to match GSK239512

Trial Locations (35)

1113

GSK Investigational Site, Sofia

1431

GSK Investigational Site, Sofia

28832

GSK Investigational Site, Achim

30559

GSK Investigational Site, Hanover

44892

GSK Investigational Site, Bochum

45525

GSK Investigational Site, Hattingen

50935

GSK Investigational Site, Cologne

50937

GSK Investigational Site, Cologne

53203

GSK Investigational Site, Pardubice

81675

GSK Investigational Site, Munich

90402

GSK Investigational Site, Nuremberg

115522

GSK Investigational Site, Moscow

117049

GSK Investigational Site, Moscow

150030

GSK Investigational Site, Yaroslavl

198103

GSK Investigational Site, Saint Petersburg

344010

GSK Investigational Site, Rostov-on-Don

394071

GSK Investigational Site, Voronezh

410060

GSK Investigational Site, Saratov

620030

GSK Investigational Site, Yekaterinburg

7560356

GSK Investigational Site, Santiago

Unknown

GSK Investigational Site, Rousse

GSK Investigational Site, Santiago

252-0997

GSK Investigational Site, Viña del Mar

100 00

GSK Investigational Site, Prague

120 00

GSK Investigational Site, Prague

150 18

GSK Investigational Site, Prague

541 01

GSK Investigational Site, Trutnov

041 66

GSK Investigational Site, Košice

054 01

GSK Investigational Site, Levoča

071 01

GSK Investigational Site, Michalovce

463-707

GSK Investigational Site, Seongnam-si

138-736

GSK Investigational Site, Seoul

BD3 0DQ

GSK Investigational Site, Bradford

CB2 2GG

GSK Investigational Site, Cambridge

G20 0XA

GSK Investigational Site, Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY